FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial
Titel:
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial
Auteur:
Malka, David François, Eric Penault-Llorca, Frédérique Castan, Florence Bouché, Olivier Bennouna, Jaafar Ghiringhelli, François de la Fouchardière, Christelle Borg, Christophe Samalin, Emmanuelle Bachet, Jean-Baptiste Raoul, Jean-Luc Miglianico, Laurent Bengrine-Lefèvre, Leila Dahan, Laetitia Lecaille, Cédric Aparicio, Thomas Stanbury, Trevor Perrier, Hervé Cayre, Anne Laurent-Puig, Pierre Gourgou, Sophie Emile, Jean-François Taïeb, Julien